OncoPharm mFOLFIRINOX
22 snips
Jan 3, 2019 Discover the latest insights on the modified FOLFIRINOX regimen for pancreatic cancer. Delve into the findings of the PRODIGE-24 study and its implications for adjuvant therapies. The conversation navigates the complexities of treatment, including potential benefits and complications like neuropathy. Engaging discussions highlight the evolution of cancer treatments and encourage audience participation in oncology topics.
AI Snips
Chapters
Books
Transcript
Episode notes
Surgery Crucial But Limited For Pancreatic Cancer
- Surgery is the only curative option for pancreatic cancer, but only about 20% of patients qualify.
- Despite surgery, long-term survival rates remain very low, under 4% at 10 years.
Gemcitabine Improves Disease-Free Survival
- Gemcitabine as adjuvant chemotherapy almost doubled median disease-free survival compared to observation.
- This improved outcomes showed progress over decades but survival remains limited.
Gemcitabine Plus Capecitabine Benefits Negative Margins
- Adding capecitabine to gemcitabine improved median overall survival modestly.
- The benefit was mostly seen in patients with negative surgical margins after resection.
